Teriflunomide
Teriflunomide is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Teriflunomide; Generic name: TERIFLUNOMIDE; Drug class: Pyrimidine Synthesis Inhibitor [EPC].
| Brand name | Teriflunomide |
|---|---|
| Generic name | TERIFLUNOMIDE |
| Drug class | Pyrimidine Synthesis Inhibitor [EPC] |
| Manufacturer | Mylan Pharmaceuticals Inc. |
| Used for | 1 INDICATIONS AND USAGE Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Teriflunomide tablets are a pyrimidine synthesis inhibitor indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 ) |
| Dosage | 2 DOSAGE AND ADMINISTRATION The recommended dose of teriflunomide tablets is 7 mg or 14 mg orally once daily. Teriflunomide tablets can be taken with or without food. Monitoring to Assess Safety: • Obtain transaminase and bilirubin levels within 6 months before initiation of teriflunomide tablets therapy. Monitor ALT levels at least monthly for six months after starting teriflunomide tablets [see Warnings and Precautions (5.1) ] . • Obtain a complete blood cell count (CBC) within 6 months before |
| Warnings | WARNING: HEPATOTOXICITY and EMBRYOFETAL TOXICITY • Hepatotoxicity: Clinically significant and potentially life-threatening liver injury, including acute liver failure requiring transplant, has been reported in patients treated with teriflunomide tablets in the postmarketing setting [see Warnings and Precautions (5.1) ] . Concomitant use of teriflunomide tablets with other hepatotoxic drugs may increase the risk of severe liver injury. Obtain transaminase and bilirubin levels within 6 months befo |
| Active ingredient(s) | TERIFLUNOMIDE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1824aae5-58af-43da-8231-435c8f118bc0 |